21 related articles for article (PubMed ID: 29048943)
1. Deletion of protein kinase B2 preserves cardiac function by blocking interleukin-6-mediated injury and restores blood pressure during angiotensin II/high-salt-diet-induced hypertension.
Yang S; Chen D; Chen F; Zhao X; Zhang Y; Li Z; Jin L; Xu Y; Sanchis D; Ye J
J Hypertens; 2018 Apr; 36(4):834-846. PubMed ID: 29120957
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of preoperative serum ferritin in hepatocellular carcinoma patients undergoing transarterial chemoembolization.
Fan M; Niu T; Lin B; Gao F; Tan B; Du X
Mol Clin Oncol; 2024 Mar; 20(3):22. PubMed ID: 38357673
[TBL] [Abstract][Full Text] [Related]
3. Clinical Value Study on Contrast-Enhanced Ultrasound Combined with Enhanced CT in Early Diagnosis of Primary Hepatic Carcinoma.
Zhang L; Gu J; Li Y; Ren Z; Zhang B; Yu Z
Contrast Media Mol Imaging; 2022; 2022():7130533. PubMed ID: 36101800
[TBL] [Abstract][Full Text] [Related]
4. Contrast-enhanced Ultrasound in evaluating of angiogenesis and tumor staging of nasopharyngeal carcinoma in nude mice.
Liang S; Gao Y; Liu Y; Qiu C; Chen Y; Zhu S
PLoS One; 2019; 14(8):e0221638. PubMed ID: 31442259
[TBL] [Abstract][Full Text] [Related]
5. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients.
Shim JH; Park JW; Kim JH; An M; Kong SY; Nam BH; Choi JI; Kim HB; Lee WJ; Kim CM
Cancer Sci; 2008 Oct; 99(10):2037-44. PubMed ID: 19016764
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of endostar combined with transcatheter arterial chemoembolization and analysis of vascular endothelial factor and C-reactive protein levels in patients with advanced hepatocellular carcinoma under contrast enhanced ultrasound.
Wang Y; Xuan Z; Zheng X; Han R; Zhou L; Liu H; Liu Y
J BUON; 2019; 24(6):2394-2401. PubMed ID: 31983111
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of endostar combined with transcatheter arterial chemoembolization and analysis of vascular endothelial factor and C-reactive protein levels in patients with advanced hepatocellular carcinoma under contrast enhanced ultrasound.
Wang Y; Xuan Z; Zheng X; Han R; Zhou L; Liu H; Liu Y
J BUON; 2020; 25(1):407-414. PubMed ID: 32277662
[TBL] [Abstract][Full Text] [Related]
8. Serial serum VEGF-A, angiopoietin-2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization.
Hsieh MY; Lin ZY; Chuang WL
Kaohsiung J Med Sci; 2011 Aug; 27(8):314-22. PubMed ID: 21802642
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of recurrence for serum hypoxia inducible factor-1α C-reaction protein in hepatocellular carcinoma patients after transcatheter arterial chemoembolization.
Jing Q; Jianyong L; Jiming Y; Shuren L; Rui W; Wei L
Indian J Cancer; 2015 Dec; 52 Suppl 2():e105-6. PubMed ID: 26728665
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patients.
Ranieri G; Ammendola M; Marech I; Laterza A; Abbate I; Oakley C; Vacca A; Sacco R; Gadaleta CD
World J Gastroenterol; 2015 May; 21(19):6018-25. PubMed ID: 26019468
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of the combination of serum levels of vascular endothelial growth factor, C-reactive protein and contrast-enhanced ultrasound in patients with primary liver cancer who underwent transcatheter arterial chemoembolization.
Xuan ZD; Zhou L; Wang Y; Zheng X
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1169-1178. PubMed ID: 29048943
[TBL] [Abstract][Full Text] [Related]
12. Contrast enhanced ultrasonography in assessing the treatment response to transarterial chemoembolization in patients with hepatocellular carcinoma.
Sparchez Z; Mocan T; Radu P; Anton O; Bolog N
Med Ultrason; 2016 Mar; 18(1):96-102. PubMed ID: 26962561
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
